Top Pharmaceuticals Acquirers (2014-2026)

Tracked deals

370

370 tracked deals across 2014-2026.

Buyer mix

Mixed buyer set

291 strategic · 187 pe

Top trend

Volume peaked in 2022

61 tracked deals announced in 2022.

Primary Insight

What Stands Out

  • Recurring strategic buyers include Bain Capital Life Sciences, Oaktree Capital Management, L.P., Vivo Capital, and Recro Pharma, Inc., alongside major pharma like Eli Lilly and Company and Vertex Pharmaceuticals Incorporated.
  • Deal rationales commonly center on program or platform expansion: precision immunology, T-cell engagers, hemato-oncology assets, and marketed therapies.
  • Geographic spread is wide, with notable recent activity in the United States, Germany, Denmark, the Netherlands, China (Sichuan), and India (Maharashtra).
  • The page also reflects different deal structures, including full share acquisitions, rights transfers, monetization of partial economic interests, and pipeline-funded mergers/spin-outs.

| Theme seen in deals | Illustrative examples from page |

Build a buyer list for your Pharmaceuticals deal

Find buyers actively acquiring pharmaceuticals companies.

Find buyers like these for your deal

Buyer Snapshot

Top Buyers

Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.

Build a buyer list for your Pharmaceuticals deal →
Buyer # Deals Focus Type
GHO Capital Partners LLP 5 Specialist healthcare private equity investor focused on ... PE
Aceto 4 Global provider and distributor of specialty ingredients ... Strategic (PE-backed)
Ampersand Capital Partners 4 Middle-market private equity firm focused on growth-orien... PE
Eli Lilly and Company 4 Global pharmaceutical company with broad neuroscience cap... Strategic
Essential Pharma 4 International specialty pharmaceutical group focused on a... Strategic (PE-backed)
H.I.G. Capital 4 Global alternative investment firm providing equity and d... PE
SK Capital Partners 4 Private investment firm focused on specialty materials, s... PE
ANI Pharmaceuticals, Inc. 3 Diversified biopharmaceutical company that develops, manu... Strategic
ARCHIMED 3 Healthcare‑focused private equity firm investing in and s... PE
B-FLEXION Life Sciences 3 Investment manager within the B-FLEXION group, focused on... PE

Acquisition Volume in Pharmaceuticals by Year

Last 9 years

Acquisition volume by year Annual acquisition counts for the last 9 years for Top Pharmaceuticals Acquirers (2014-2026). 3 2018 16 2019 32 2020 50 2021 61 2022 44 2023 54 2024 55 2025 ~64 est. 51 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Viatris to Acquire Pacira BioSciences for $1.65 Billion
    October 9, 2026
    Buyer
    Viatris
    Target
    Pacira BioSciences
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Buyout

    Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, valuing the deal at approximately $1.65 billion. The acquisition is intended to strengthen Viatris’ non-opioid pain management portfolio by adding products such as EXPAREL and ZILRETTA and leveraging Viatris’ commercial and international footprint.

  • AmyriAD Therapeutics Acquires Recognify Life Sciences and RL-007
    October 8, 2026
    Buyer
    AmyriAD Therapeutics
    Target
    Recognify Life Sciences, RL-007 (inidascamine)
    Seller
    Recognify shareholders (atai Life Sciences, Catalio Capital Management, Sudhoff Family Office)
    Industry
    Pharmaceuticals
    Location
    Oregon, United States
    Type
    Buyout

    AmyriAD Therapeutics acquired Recognify Life Sciences and its lead clinical-stage program, RL-007 (inidascamine), to expand its pipeline for cognitive impairment. The transaction brings RL-007 into AmyriAD’s cognition-focused portfolio alongside its existing Alzheimer’s program (ismidenon/AD-101).

  • Shionogi Inc. to Acquire IntraBio Inc.
    October 5, 2026
    Buyer
    Shionogi Inc.
    Target
    IntraBio Inc.
    Seller
    IntraBio’s existing shareholders, including individuals, trusts, and corporate entities (identities undisclosed)
    Industry
    Pharmaceuticals
    Location
    Texas, United States
    Type
    Buyout

    Shionogi Inc., a U.S. subsidiary of Shionogi & Co., signed an agreement to acquire all outstanding shares of IntraBio Inc. for $2.0 billion upfront, making IntraBio a wholly owned subsidiary. The proposed acquisition would add AQNEURSA and global rights to the drug, along with IntraBio’s rare-disease expertise and pipeline capabilities, to Shionogi’s portfolio; closing is subject to customary conditions and was planned for November–December 2026.

  • GE HealthCare to Acquire SOFIE Biosciences for $945 Million
    October 5, 2026
    Buyer
    GE HealthCare
    Target
    SOFIE Biosciences
    Seller
    Trilantic North America
    Industry
    Pharmaceuticals
    Location
    Virginia, United States
    Type
    Buyout

    GE HealthCare entered into a definitive agreement to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash. SOFIE, a U.S. contract manufacturer of PET radiopharmaceuticals, will expand GE HealthCare’s U.S. manufacturing and distribution network; the transaction is expected to close in the first half of 2027, subject to regulatory approvals and other closing conditions.

  • Samfara Acquires Chr. Olesen Synthesis
    October 2, 2026
    Buyer
    Samfara, Thomas Moestrup
    Target
    Chr. Olesen Synthesis
    Seller
    Chr. Olesen, funds managed by Signet Healthcare Partners
    Industry
    Pharmaceuticals
    Location
    Denmark
    Type
    Buyout

    Samfara has completed the acquisition of Chr. Olesen Synthesis, a Danish developer and manufacturer of controlled-substance active pharmaceutical ingredients (APIs) and advanced intermediates. The deal is Samfara’s first investment, with CEO Thomas Moestrup investing alongside Samfara; financial terms were not disclosed.

  • Webster Equity Partners to Acquire Lifecore Biomedical (Up to $663.7M)
    September 28, 2026
    Buyer
    Webster Equity Partners, MidCap Financial Trust, MSD Partners, Alcon Research
    Target
    Lifecore Biomedical
    Industry
    Pharmaceuticals
    Location
    Minnesota, United States
    Type
    Buyout

    Lifecore Biomedical has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million, subject to performance milestones tied to contingent value rights (CVRs). Webster will acquire all outstanding common shares for $6.28 per share in cash at closing plus one CVR per share, with additional payments possible based on revenue and EBITDA milestones.

  • Telix Pharmaceuticals to Acquire ITM Isotope Technologies Munich to Build Radiopharmaceutical Powerhouse
    September 21, 2026
    Buyer
    Telix Pharmaceuticals
    Target
    ITM Isotope Technologies Munich
    Seller
    ITM sellers (not individually named in the article)
    Industry
    Pharmaceuticals
    Location
    Germany
    Type
    Buyout

    Telix Pharmaceuticals has signed an agreement to acquire 100% of ITM Isotope Technologies Munich in a deal valuing it at $1.65 billion upfront, with up to $700 million in additional milestone payments. The acquisition combines Telix’s radiopharmaceutical development and precision medicine capabilities with ITM’s large-scale isotope manufacturing, global distribution, and late-stage therapeutic pipeline, aiming to create a more vertically integrated radiopharmaceutical platform.

  • Lisata Therapeutics Acquires Marea Therapeutics in Stock-for-Stock Deal and Concurrent $225M Private Placement
    September 17, 2026
    Buyer
    Lisata Therapeutics, Inc., RA Capital Management, Forbion, Third Rock Ventures, Alpha Wave, Perceptive Advisors, Sofinnova Investments, Omega Funds, Surveyor Capital (a Citadel company), Columbia Threadneedle Investments, Nantahala Capital, Affinity Asset Advisors, LLC, venBio, Rock Springs Capital
    Target
    Marea Therapeutics, Inc.
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Buyout

    Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock transaction to build a combined portfolio focused on next-generation medicines for cardioendocrine diseases. Concurrently, Lisata raised $225 million through an oversubscribed private placement with leading life sciences and institutional investors to fund clinical milestones into 2028.

  • GSK Agrees to Acquire Chimagen Biosciences Trispecific T-Cell Engager Program
    September 15, 2026
    Buyer
    GSK
    Target
    Chimagen Biosciences
    Industry
    Pharmaceuticals
    Location
    Sichuan, China
    Type
    Buyout

    GSK has agreed to acquire full global rights to Chimagen Biosciences’ potential best-in-class trispecific T-cell engager program for multiple myeloma in a deal worth up to $750 million. The agreement includes an upfront payment and development and commercial milestone payments for the privately held Chimagen.

  • COSCIENS Biopharma Acquires Nualtis Corp.
    September 10, 2026
    Buyer
    COSCIENS Biopharma Inc.
    Target
    Nualtis Corp.
    Seller
    AtaiBeckley Inc.
    Industry
    Pharmaceuticals
    Location
    Canada
    Type
    Buyout

    COSCIENS Biopharma Inc. acquired Nualtis Corp., a Montreal-based specialty pharmaceutical technology company focused on proprietary oral thin-film drug delivery technologies for human and animal health. The deal was completed under a share purchase agreement with AtaiBeckley Inc. for an initial cash payment of $9 million plus a $6 million deferred payment, with additional earn-out payments potentially payable through 2030.

  • Vertex Pharmaceuticals Acquires Crinetics Pharmaceuticals
    September 1, 2026
    Buyer
    Vertex Pharmaceuticals Incorporated
    Target
    Crinetics Pharmaceuticals, Inc.
    Industry
    Pharmaceuticals
    Location
    California, United States
    Type
    Buyout

    Vertex Pharmaceuticals Incorporated completed its acquisition of Crinetics Pharmaceuticals, Inc. on September 1, 2026, in a transaction valued at approximately $10 billion in equity value. The acquisition adds PALSONIFY, atumelnant and other pipeline programs, establishing rare endocrine diseases as a new growth area for Vertex.

  • RedHill Biopharma Divests Talicia to an Apotex Subsidiary for $18M Upfront Plus Milestones
    August 31, 2026
    Buyer
    Apotex Health Corp. (subsidiary)
    Target
    Talicia
    Seller
    RedHill Biopharma Ltd.
    Industry
    Pharmaceuticals
    Location
    Israel
    Type
    Divestiture

    RedHill Biopharma divested its 70% interest in the Talicia business to a subsidiary of Apotex Health for $18 million upfront cash, plus up to $35 million in worldwide net sales milestone payments. The company said proceeds will strengthen liquidity and fund the next stage of RedHill’s gastrointestinal commercial expansion, including scaling its GI franchise and pursuing new high-value FDA-approved opportunities.

  • Teva to Acquire IGALMI (Dexmedetomidine Sublingual Film) Assets from BioXcel Therapeutics in Court-Supervised Sale
    August 28, 2026
    Buyer
    Teva Pharmaceuticals International GmbH
    Target
    IGALMI (dexmedetomidine sublingual film) assets from BioXcel Therapeutics, Inc. and its affiliates (including BXCL501 product-related rights)
    Seller
    BioXcel Therapeutics, Inc. and its affiliates
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Buyout

    Teva Pharmaceuticals announced it made a bid to acquire worldwide rights to IGALMI (dexmedetomidine sublingual film) via a court-supervised bankruptcy sale process under Section 363 of the U.S. Bankruptcy Code. The deal would be for upfront payments plus contingent payments and remains subject to being selected as the successful bidder and approval by the bankruptcy court, among other closing conditions.

  • Werewolf Therapeutics and Ambros Therapeutics Merge in $150M PIPE to Advance Neridronate Phase 3
    August 23, 2026
    Buyer
    Ambros Therapeutics
    Target
    Ambros Therapeutics, Werewolf Therapeutics
    Industry
    Pharmaceuticals
    Location
    California, United States
    Type
    Buyout

    Werewolf Therapeutics and Ambros Therapeutics entered into a definitive all-stock merger agreement, with a concurrently announced, oversubscribed $150 million private placement expected to fund development of neridronate through pivotal Phase III results and a planned FDA submission. The combined company will operate as Ambros Therapeutics, be headquartered in San Diego, and is expected to trade on Nasdaq as AMBX.

  • Ipsen completes acquisition of Kartos Therapeutics
    August 21, 2026
    Buyer
    Ipsen
    Target
    Kartos Therapeutics
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Buyout

    Ipsen has completed its acquisition of Kartos Therapeutics, adding the late-stage MDM2 inhibitor navtemadlin to its oncology pipeline. Navtemadlin is in Phase III development for myelofibrosis as an add-on therapy to ruxolitinib for patients with a suboptimal response to standard treatment.

  • LEO Pharma to Acquire Worldwide Rights to Dersimelagon From Tanabe Pharma
    August 18, 2026
    Buyer
    LEO Pharma
    Target
    Dersimelagon (worldwide rights)
    Seller
    Tanabe Pharma
    Industry
    Pharmaceuticals
    Location
    Denmark
    Type
    Buyout

    LEO Pharma entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma. The oral, once-daily MC1R agonist is in development for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), with LEO Pharma expecting pre-launch investments in 2026 and a potential launch in 2027. The deal includes up to USD 435 million in upfront and near-term milestone payments plus potential downstream milestones and tiered royalties.

  • Alfasigma to Acquire Nordic Group B.V. (Nordic Pharma)
    August 11, 2026
    Buyer
    Alfasigma S.p.A.
    Target
    Nordic Group B.V. (Nordic Pharma), Nordic Group B.V. and its subsidiaries
    Seller
    SEVER Life Sciences B.V.
    Industry
    Pharmaceuticals
    Location
    Netherlands
    Type
    Buyout

    Alfasigma S.p.A. has entered into a share purchase agreement with SEVER Life Sciences B.V. to acquire 100% of the shares of Nordic Group B.V. and its subsidiaries (Nordic Pharma). The deal will expand Alfasigma’s specialty rheumatology offering, including Nordic Pharma’s rheumatoid arthritis Nordimet (methotrexate) franchise, while also strengthening its commercial footprint in Europe, Canada, and Japan.

  • Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics
    July 21, 2026
    Buyer
    Kaveri Therapeutics Inc.
    Target
    LNP7457 (PRMT5) oncology program, LNP8701 (SOS1) oncology program
    Seller
    Lupin Inc.
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Divestiture

    Lupin announced a strategic spin-out of two oncology programs—LNP7457 (PRMT5) and LNP8701 (SOS1)—into Kaveri Therapeutics through its wholly owned subsidiary, Lupin Inc. Lupin Inc. will hold a significant equity stake, provide seed funding, and grant exclusive rights to the programs as Kaveri advances them through global clinical trials.

  • Warburg Pincus Acquires Integrace Private Limited
    July 15, 2026
    Buyer
    Warburg Pincus
    Target
    Integrace Private Limited
    Seller
    True North Fund VI LLP, V-Sciences Investments Pte Ltd, Temasek Holdings, True North
    Industry
    Pharmaceuticals
    Location
    India
    Type
    Buyout

    Warburg Pincus acquired 100% of Integrace Private Limited, a domestic orthopedics and gynecology-focused pharmaceutical formulations company, leading to full exits for existing shareholders True North Fund VI LLP and Temasek (via V-Science Investments). Industry veteran Rehan Khan was appointed CEO to lead Integrace’s next phase of growth as part of Warburg Pincus’ therapy-focused platform strategy.

  • Bayer Secures €3 Billion From Apollo for Stake in Long-Acting Reversible Contraceptives Business
    July 12, 2026
    Buyer
    Bayer AG, Apollo-managed funds and affiliates
    Target
    Bayer long-acting reversible contraceptives (LARC) business (held in newly established entity)
    Industry
    Pharmaceuticals
    Location
    North Rhine-Westphalia, Germany
    Type
    Recapitalization

    Bayer will secure €3 billion in equity capital via an agreement with Apollo, with Apollo-managed funds taking a minority, non-controlling stake in a newly established entity holding Bayer’s long-acting reversible contraceptives (LARC) business. Bayer will retain a majority stake and full operational control, and the LARC business will remain part of Bayer’s Pharmaceuticals Division and be fully consolidated for financial reporting purposes. The transaction is expected to close in Q3 2026, subject to antitrust approval and customary closing conditions.

  • Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10B
    July 5, 2026
    Buyer
    Vertex Pharmaceuticals
    Target
    Crinetics Pharmaceuticals, Inc.
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Buyout

    Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for total equity value of about $10 billion ($8.8 billion net of estimated cash acquired). The deal—priced at $85 per share—was announced as a definitive agreement and is expected to close in the third quarter of 2026, subject to regulatory approvals and Crinetics shareholder approval.

  • Aurobindo Pharma USA Completes Acquisition of Lannett Company
    June 30, 2026
    Buyer
    Aurobindo Pharma USA Inc. (APUSA), Aurobindo Pharma Limited
    Target
    Lannett Company, Inc., USA, Lannett Company LLC
    Seller
    Lannett Seller Holdco, Inc.
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Buyout

    Aurobindo Pharma USA Inc. (APUSA), a wholly owned subsidiary of Aurobindo Pharma Limited, has completed its acquisition of Lannett Company, Inc., USA from Lannett Seller Holdco, Inc. The deal received approval from the U.S. Federal Trade Commission on June 18, 2026, and effective June 29, 2026 Lannett became a wholly owned subsidiary of APUSA.

  • Zymeworks to Acquire Theravance Biopharma for $929 Million
    June 29, 2026
    Buyer
    Zymeworks Inc., OMERS Life Sciences
    Target
    Theravance Biopharma, Inc.
    Industry
    Pharmaceuticals
    Location
    Ireland
    Type
    Buyout

    Zymeworks entered into a definitive agreement to acquire Theravance Biopharma for $17.00 per share in cash, valuing the transaction at approximately $929 million. Under the deal, Theravance Biopharma shareholders also receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future monetization of ampreloxetine over the next ten years.

  • Laprophan Group Acquires Controlling Stake in Rivopharm
    June 17, 2026
    Buyer
    Laprophan Group, Europhan
    Target
    Rivopharm
    Industry
    Pharmaceuticals
    Location
    Ticino, Switzerland
    Type
    Buyout

    Laprophan Group completed the acquisition of a controlling stake in Rivopharm, a Switzerland-based specialty pharmaceutical company focused on specialty medicines, dossier development, and complex formulations. The deal strengthens Laprophan’s European footprint and supports its ambition to build an international pharmaceutical platform across Europe, Africa, the Middle East, and selected global markets.

  • Eli Lilly Acquires 4E Therapeutics
    June 16, 2026
    Buyer
    Eli Lilly and Company
    Target
    4E Therapeutics, Inc.
    Industry
    Pharmaceuticals
    Location
    Texas, United States
    Type
    Buyout

    Eli Lilly and Company acquired Austin-based neuroscience company 4E Therapeutics to advance its non-opioid chronic pain pipeline. 4E is developing orally available MNK inhibitors targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons, including lead candidate 4ET1103 that entered human Phase 1 trials with a favorable safety profile.

  • Cosmos Health Signs LOI to Acquire Doc Pharma S.A.
    June 11, 2026
    Buyer
    Cosmos Health Inc.
    Target
    Doc Pharma S.A.
    Industry
    Pharmaceuticals
    Location
    Greece
    Type
    Buyout

    Cosmos Health Inc. has entered into a non-binding letter of intent (LOI) to acquire 100% of Doc Pharma S.A., a GMP-licensed European pharmaceutical manufacturer. The proposed deal is intended to deepen Cosmos Health’s vertical integration by expanding manufacturing capacity, product portfolio, and related R&D capabilities, and is expected to be accretive to assets, profitability, and cash flow over time.

  • SK Capital Partners' Buyout and Recapitalization of Apotex Leading to IPO
    June 10, 2026
    Buyer
    SK Capital Partners
    Target
    Apotex Health Corp.
    Seller
    Sherman estate
    Industry
    Pharmaceuticals
    Location
    Canada
    Type
    Recapitalization

    SK Capital Partners acquired control of Apotex from the Sherman estate in 2023, then reoriented the business with cost cuts, geographic focus, and portfolio acquisitions (including biosimilars and specialty drugs). Over the following three years, SK Capital and the Sherman family completed a debt-heavy leveraged buyout and extracted roughly $2 billion via dividends and share repurchases, culminating in Apotex’s IPO in June 2026.

  • GSK to Acquire Nuvalent for $10.6 Billion
    June 9, 2026
    Buyer
    GSK, Deerfield Management (announced as Nuvalent portfolio owner; not the acquirer)
    Target
    Nuvalent, Inc.
    Industry
    Pharmaceuticals
    Location
    Massachusetts, United States
    Type
    Buyout

    GSK announced an agreement to acquire clinical-stage biopharmaceutical company Nuvalent for $10.6 billion to expand its lung cancer oncology portfolio. The deal will include three non-small cell lung cancer (NSCLC) programs, led by zidesamtinib and neladalkib, and is expected to drive revenue growth beginning in 2027.

  • Servier Acquires Sevasemten and Edgewise Therapeutics' Muscular Dystrophy Business for Up to $2.65 Billion
    June 1, 2026
    Buyer
    Servier
    Target
    sevasemten (asset/program), Edgewise Therapeutics muscular dystrophy business
    Seller
    Edgewise Therapeutics, Inc.
    Industry
    Pharmaceuticals
    Location
    Colorado, United States
    Type
    Divestiture

    Servier acquired sevasemten and Edgewise Therapeutics' muscular dystrophy business in a transaction with total potential consideration of up to $2.65 billion, including $1.55 billion upfront and up to $1.1 billion in regulatory and commercial milestones. The deal closes Servier into Becker and Duchenne muscular dystrophy, while Edgewise transitions to a cardiovascular-focused pipeline centered on EDG-7500 and EDG-15400.

  • Eli Lilly Acquires Curevo (Shingles) and LimmaTech Biologics (Bacterial Vaccines)
    May 26, 2026
    Buyer
    Eli Lilly and Company
    Target
    Curevo Vaccine (Curevo), LimmaTech Biologics AG (LimmaTech Biologics)
    Industry
    Pharmaceuticals
    Location
    Switzerland
    Type
    Buyout

    Eli Lilly entered definitive agreements to acquire Curevo Vaccine and LimmaTech Biologics as part of a broader expansion of its infectious disease R&D platform. Lilly will acquire Curevo for up to $1.5 billion and LimmaTech Biologics for up to $780 million, with upfront and additional milestone-based payments.

  • TopGum Industries Acquires PL Developments’ U.S. Gummy Manufacturing Operations
    May 5, 2026
    Buyer
    TopGum Industries Ltd.
    Target
    P26L Developments LLC, P L Developments LLC, PL Developments LLC (PLD)
    Industry
    Pharmaceuticals
    Location
    New York, United States
    Type
    Buyout

    TopGum Industries Ltd. completed the acquisition of the U.S. gummy manufacturing operations of P26L/PL Developments LLC (PLD). TopGum also entered a long-term commercial partnership with PLD under which PLD will commercialize and distribute TopGum-manufactured gummy products to leading U.S. retailers under store-brand labels.

  • ACEA Therapeutics and ACEA Pharma to Acquire Phoenix Asia Holdings’ ACEA Pharma Stake in $1B Stock Deal
    May 5, 2026
    Buyer
    ACEA Therapeutics, Inc., ACEA Pharma, Inc.
    Target
    ACEA Pharma, Inc.
    Seller
    Phoenix Asia Holdings Limited
    Industry
    Pharmaceuticals
    Location
    California, United States
    Type
    Buyout

    Scilex Holding Company’s indirect subsidiaries ACEA Therapeutics, Inc. and ACEA Pharma, Inc. entered into a stock acquisition agreement with Phoenix Asia Holdings Limited to acquire 100% of ACEA Pharma. The transaction is valued at $1 billion and will issue Phoenix shares to ACEA Therapeutics, with Phoenix expected to be renamed the “Go-Forward Company” ACEA Pharma and listed on Nasdaq after closing.

  • Teva Pharmaceuticals Acquires Emalex Biosciences
    May 1, 2026
    Buyer
    Teva Pharmaceuticals, Teva Pharmaceutical Industries Ltd.
    Target
    Emalex Biosciences, Emalex
    Seller
    Paragon Biosciences
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Buyout

    Teva Pharmaceuticals has acquired Emalex Biosciences in a definitive transaction to add ecopipam, a first-in-class investigational therapy for pediatric Tourette syndrome, to Teva’s neuroscience pipeline. The deal includes $700 million paid at closing, with up to $200 million in additional commercial milestone payments and net sales-based royalties, subject to regulatory approval.

  • Eli Lilly and Company to Acquire Ajax Therapeutics, Inc.
    April 27, 2026
    Buyer
    Eli Lilly and Company
    Target
    Ajax Therapeutics, Inc.
    Industry
    Pharmaceuticals
    Location
    New York, United States
    Type
    Buyout

    Eli Lilly and Company announced a definitive agreement to acquire Ajax Therapeutics, Inc. in a deal valued at up to $2.3 billion, including upfront and milestone-based payments. The acquisition is intended to expand Lilly’s oncology pipeline with Ajax’s lead candidate, AJ1-11095, a Type II JAK2 inhibitor in Phase 1 development for myelofibrosis, including patients previously treated with Type I JAK2 inhibitors.

  • Apotex Acquires Cumberland Pharmaceuticals' U.S. Branded Portfolio for $100 Million
    April 23, 2026
    Buyer
    Apotex, Apotex Health Corp.
    Target
    Cumberland Pharmaceuticals Inc.
    Seller
    Cumberland Pharmaceuticals Inc.
    Industry
    Pharmaceuticals
    Location
    Tennessee, United States
    Type
    Divestiture

    Apotex entered into an agreement with Cumberland Pharmaceuticals to integrate Cumberland’s U.S. branded pharmaceutical business into Apotex. Under the terms, Apotex will acquire Cumberland’s line of branded pharmaceuticals for $100 million in cash, while Cumberland retains its pipeline candidates (including ifetroban) and its majority ownership in Cumberland Emerging Technologies Inc.

  • Everstone Capital Invests $270 Million in Apothecon Group (Apothecon Pharmaceuticals and Navinta)
    April 14, 2026
    Buyer
    Everstone Capital
    Target
    Apothecon Pharmaceuticals Private Limited, Navinta III Inc., Apothecon Group
    Seller
    Apothecon founding promoters (Dr. Mahendra Patel and Joe Renner) (retaining a meaningful stake)
    Industry
    Pharmaceuticals
    Location
    Gujarat, India
    Type
    Growth capital

    Singapore-headquartered private equity firm Everstone Capital has invested close to $270 million for a substantial stake in Apothecon Group, formed by India-based Apothecon Pharmaceuticals and US-based Navinta. Everstone said it will accelerate the group’s product pipeline, expand commercial reach into new geographies, and pursue complementary acquisitions, while the founding promoters will retain meaningful ownership.

  • Gilead Sciences and Lakefront Biotherapeutics Acquire Ouro Medicines
    March 27, 2026
    Buyer
    Gilead Sciences, Inc., Lakefront Biotherapeutics
    Target
    Ouro Medicines
    Industry
    Pharmaceuticals
    Location
    California, United States
    Type
    Buyout

    Gilead Sciences agreed to acquire Ouro Medicines to expand its inflammation and immunology pipeline with gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases. The deal adds gamgertamig to Gilead’s portfolio and establishes Lakefront Biotherapeutics’ clinical development pipeline, with Lakefront overseeing Phase 1/2 studies and sharing upfront/milestone economics.

  • Merck Acquires Terns Pharmaceuticals
    March 26, 2026
    Buyer
    Merck
    Target
    Terns Pharmaceuticals
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Buyout

    Merck has agreed to acquire clinical-stage oncology company Terns Pharmaceuticals for approximately $6.7 billion (53.00 per share in cash). The deal is intended to add Terns’ lead asset TERN-701, an investigational oral allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia, to Merck’s hematology/oncology pipeline.

  • Paratek Pharmaceuticals Completes Combination with Radius Health
    March 20, 2026
    Buyer
    Paratek Pharmaceuticals, Inc., B-FLEXION Life Sciences, Blackstone Credit & Insurance, Sixth Street, Oaktree Capital Management, L.P., Silver Point Capital, Pharmakon Advisors, LP
    Target
    Radius Health, Inc.
    Industry
    Pharmaceuticals
    Location
    Pennsylvania, United States
    Type
    Buyout

    Paratek Pharmaceuticals completed its combination with Radius Health, adding Radius’s osteoporosis therapy TYMLOS (abaloparatide) to Paratek’s specialty pharmaceutical portfolio. The combined company is expected to generate nearly $1 billion in revenue in 2026 and expands the platform across multiple high-need therapeutic areas.

  • Servier Acquires Day One Biopharmaceuticals to Expand Rare Oncology Portfolio
    March 6, 2026
    Buyer
    Servier
    Target
    Day One Biopharmaceuticals, Inc.
    Industry
    Pharmaceuticals
    Location
    California, United States
    Type
    Buyout

    Servier and Day One Biopharmaceuticals entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, valuing the deal at approximately $2.5 billion. The acquisition is expected to close in the second quarter of 2026 and is intended to strengthen Servier’s rare oncology and pediatric low-grade glioma positioning while expanding its clinical-stage pipeline.

  • Kuva Labs Acquires Lisata Therapeutics
    March 6, 2026
    Buyer
    Kuva Labs, Inc.
    Target
    Lisata Therapeutics, Inc.
    Industry
    Pharmaceuticals
    Location
    New Jersey, United States
    Type
    Buyout

    Kuva Labs, Inc. has entered into a definitive agreement to acquire Lisata Therapeutics, Inc. for $5.00 per share in cash, plus a contingent value right (CVR) that could pay an additional $1.00 per share upon an FDA-related regulatory milestone tied to certepetide. The transaction is expected to close in the second quarter of 2026, subject to customary tender offer conditions, including tender of a majority of Lisata’s outstanding shares.

  • Grünenthal Acquires Kyowa Kirin’s 49% Stake in Grünenthal Meds JV
    March 2, 2026
    Buyer
    Grünenthal
    Target
    Grünenthal Meds
    Seller
    Kyowa Kirin International
    Industry
    Pharmaceuticals
    Location
    United Kingdom
    Type
    Buyout

    Grünenthal acquired Kyowa Kirin International’s 49% stake in Grünenthal Meds, taking full ownership of the joint venture created in 2023 to market Grünenthal’s established medicines portfolio. The JV manages a portfolio of 12 established brands across six therapeutic areas and more than 60 markets, with key products including Abstral, PecFent, Moventig, and Adcal-D3.

  • Asahi Kasei to Acquire Aicuris Anti-infective Cures AG
    February 26, 2026
    Buyer
    Asahi Kasei
    Target
    Aicuris Anti-infective Cures AG
    Industry
    Pharmaceuticals
    Location
    Germany
    Type
    Buyout

    Asahi Kasei entered into a definitive agreement to acquire Aicuris Anti-infective Cures AG, a German biopharmaceutical company, for approximately €780 million. The acquisition is designed to expand Asahi Kasei’s specialty pharmaceutical platform into severe infectious diseases and to complement its existing transplant and nephrology franchises. A second article reports Asahi Kasei completed the acquisition.

  • Alkermes plc Acquires Avadel Pharmaceuticals plc
    February 12, 2026
    Buyer
    Alkermes plc
    Target
    Avadel Pharmaceuticals plc
    Seller
    Avadel Pharmaceuticals plc shareholders
    Industry
    Pharmaceuticals
    Location
    Ireland
    Type
    Buyout

    Alkermes plc completed its all-cash acquisition of Avadel Pharmaceuticals plc under an Irish High Court‑sanctioned scheme of arrangement, adding Avadel's FDA‑approved product LUMRYZ to Alkermes' commercial portfolio. The deal accelerates Alkermes' entry into the sleep medicine market, is expected to be accretive in 2026, and includes Avadel's clinical candidate valiloxybate.

  • Sobi Completes Acquisition of Arthrosi Therapeutics for Up to $1.5 Billion
    February 9, 2026
    Buyer
    Swedish Orphan Biovitrum AB (publ) (Sobi)
    Target
    Arthrosi Therapeutics, Inc.
    Industry
    Pharmaceuticals
    Location
    California, United States
    Type
    Buyout

    Swedish Orphan Biovitrum AB (Sobi) has completed its acquisition of Arthrosi Therapeutics, purchasing all outstanding shares of Arthrosi’s common stock and common stock equivalents. The deal adds pozdeutinurad (AR882), a once-daily oral URAT1 inhibitor in two fully enrolled Phase 3 studies for progressive and tophaceous gout.

  • BioSelective Capital Investments Acquires BioDuro's Irvine Drug Product Operations to Form Forma Life Sciences
    February 4, 2026
    Buyer
    BioSelective Capital Investments, Shayan Enterprises, LLC
    Target
    BioDuro's Irvine drug product development and manufacturing operations (now Forma Life Sciences, Inc.)
    Seller
    BioDuro, Advent International
    Industry
    Pharmaceuticals
    Location
    California, United States
    Type
    Divestiture

    BioSelective Capital Investments, together with Shayan Enterprises, LLC, acquired BioDuro’s drug product development and manufacturing operations in Irvine, California and formed Forma Life Sciences, Inc. The transaction transfers two U.S.-based oral solid dosage development and manufacturing facilities (≈65,000 sq ft and ≈40,000 sq ft) to the new Delaware-held company; BioDuro (an Advent portfolio company) sold the assets.

  • BC Partners and Bpifrance Acquire Biogaran from Servier
    January 30, 2026
    Buyer
    BC Partners, Bpifrance (Bpifrance Investissement)
    Target
    Biogaran
    Seller
    Servier
    Industry
    Pharmaceuticals
    Location
    France
    Type
    Buyout

    BC Partners and Bpifrance have completed the acquisition of Biogaran from Servier. The deal is supported by regulatory approvals (including EU clearances and French foreign investment screening), after a favourable opinion from Biogaran’s Social and Economic Committee.

  • Mirum Pharmaceuticals Acquires Bluejay Therapeutics
    January 26, 2026
    Buyer
    Mirum Pharmaceuticals
    Target
    Bluejay Therapeutics
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Buyout

    Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, adding brelovitug — a late‑stage monoclonal antibody for chronic hepatitis delta virus (HDV) — to its rare liver disease pipeline. The deal gives Mirum worldwide rights to the AZURE Phase 3 program and includes a combination of cash and Mirum common stock with potential sales‑based milestone payments; Mirum also raised approximately $268.5M in concurrent financing to support development and commercialization.

  • Agno Pharma Acquires Actylis Eugene (Legacy Cascade Chemistry) in Eugene, Oregon
    January 15, 2026
    Buyer
    Agno Pharma
    Target
    Actylis Eugene (legacy Cascade Chemistry business)
    Seller
    Actylis
    Industry
    Pharmaceuticals
    Location
    Oregon, United States
    Type
    Buyout

    Agno Pharma has acquired Actylis Eugene, the legacy Cascade Chemistry manufacturing asset in Eugene, Oregon, expanding Agno's U.S. cGMP API development and manufacturing footprint. The site includes a 16,000 sq. ft. R&D lab and a newly constructed 30,000 sq. ft. GMP manufacturing facility, enhancing Agno's capabilities to support biotech and pharmaceutical clients from early-phase through commercial API production.

  • B-FLEXION Life Sciences to Acquire Remaining 57% of Radius Health from Patient Square and Webster Equity Partners
    January 12, 2026
    Buyer
    B-FLEXION Life Sciences
    Target
    Radius Health
    Seller
    Affiliates of Patient Square Capital, Webster Equity Partners
    Industry
    Pharmaceuticals
    Location
    Massachusetts, United States
    Type
    Buyout

    B-FLEXION Life Sciences has agreed to purchase the remaining 57% interest in Radius Health held by affiliates of Patient Square Capital and Webster Equity Partners. Radius, a specialty biopharmaceutical focused on bone health, had been taken private by B-FLEXION and Patient Square in August 2022. The transaction is expected to close by the end of Q1 2026.

Full Export

Purchase this data

Get the full acquisitions list for this page as CSV + XLSX.

Purchase this data

Build a buyer list for your Pharmaceuticals deal

Find buyers actively acquiring pharmaceuticals companies.

Apply as a Buyer

Frequently Asked Questions

What types of deals are covered in these Pharmaceuticals acquisitions?

The page includes full acquisitions, merger agreements, rights transfers (worldwide rights), and transactions that monetize remaining economic interests or involve structured milestone payments.

Which recent deals are highlighted on the page?

Examples include GSK acquiring rights to a trispecific T-cell engager program from Chimagen Biosciences; Eli Lilly and Company acquiring Merida Biosciences; and Vertex Pharmaceuticals Incorporated acquiring Crinetics Pharmaceuticals.

Are the acquisitions focused only on the United States?

No. Recent locations listed include the United States, Sichuan (China), Denmark, the Netherlands, Maharashtra (India), and North Rhine-Westphalia (Germany).

Do deals focus on specific therapeutic areas?

Yes. The page shows emphasis on areas such as precision immunology, T-cell engager programs, rare-endocrine therapies, hemato-oncology, rheumatology, and gastrointestinal franchise commercialization (in the context of milestone-linked consideration for Talicia).

Related Acquisition Pages

Pharmaceuticals Buyers & Acquisitions in Canada Private Equity-Backed Pharmaceuticals Buyers Pharmaceuticals Acquisitions in 2026 Pharmaceuticals Acquisitions in Oregon Pharmaceuticals Acquisitions in Texas Pharmaceuticals Acquisitions in Virginia Pharmaceuticals Acquisitions in Minnesota Pharmaceuticals Acquisitions in California Pharmaceuticals Acquisitions in Massachusetts

Related articles